< %=imgalt%>
Home / Technology News / 2008 / January 2008 / January 23, 2008
Malaria vaccine trial in Mali shows early promising results

Technology News

Stem cell heart surgery may spell the end for transplantation
British scientists have developed a new technique that can rebuild a severely damaged heart, and one day, might replace the need for transplantation. ANI

A new insight into the turbulent atmosphere of Venus
New images taken by instruments on board ESAs (European Space Agencys) Venus Express have provided insight into the turbulent atmosphere of our neighbouring planet. ANI

ESA tests laser to measure atmospheric CO2
A recent ESA (European Space Agency) campaign has demonstrated how a technique using lasers could be employed to measure carbon dioxide (CO2) in the atmosphere. ANI

Malaria vaccine trial in Mali shows early promising results

A malaria vaccine trial in Mali conducted by researchers at the Malaria Research and Training Center at the University of Bamako, Mali, has shown early promising results.

Washington, Jan 23 : A malaria vaccine trial in Mali conducted by researchers at the Malaria Research and Training Center at the University of Bamako, Mali, has shown early promising results.

In the study, the researchers found that a candidate malaria vaccine, designed to block the malaria parasite from entering human blood cells, was safe and elicited strong immune responses in the 40 Malian adults who received it.

The small clinical trial, conducted by lead author Mahamadou A. Thera M.D., MPH, and colleagues, was the first to test this vaccine candidate in a malaria-endemic country.

In the study, a total of 60 participants were assigned at random to receive either a full or half-dose of the candidate malaria vaccine or a licensed rabies vaccine, which served as a control.

Each volunteer was given three injections, spaced one month apart. Injections began in late December 2004, at the end of the malaria transmission season.

It was found that all volunteers had significant levels of antibodies against malaria parasites detectable in their blood at the beginning of the trial, signalling that they had prior exposure to malaria parasites.

People who received the candidate vaccine tolerated it very well and experienced a significant boost in levels of vaccine-specific antibodies, while those who received the rabies vaccine had declining levels of antibodies as the rainy season receded.

ANI

December 5, 2008

December 4, 2008

December 3, 2008

December 2, 2008

December 1, 2008

November 30, 2008